Replies to post #282694 on Avid Bioservices Inc (CDMO)

[biopharm]

Clearly Peregrine has downsized the Bavi project.

I don't consider downsizing .... as being getting PS Targeting into the hands of Memorial Sloan Kettering, AstraZeneca, Merck, NCCN...etc and not to mention, at least get some more top Docs working with PS Targeting such as Dr. Jedd Wolchok and Dr. Bernard Fox

Downsizing? I think not

Broadening and upsizing via PS Targeting biomarketers than will allow for many quicker, FDA approvals in the future? I think yes

I think what some may fail to understand, is one does not have to spend and have a $100 Million phase III trial to consider the company moving forward...

The more hands that PS Targeting gets into and there were dozens of collaborations before there were dozens of collaborations.... yet we publicly don't even know all of them yet

Happy New Year to All : )

[biopharm]

I see Peregrine's re-focusing the company on Avid as smart.

I agree 100%.... I imagine for Fargo forces would like to not see Avid in the picture and force Peregrine into a spiral, like many small biotechs before them

[jakedogman1]

"Clearly Peregrine has downsized the Bavi project. I just hope there is still value to be had in the anti-PS project."

Hopefully you are wrong on this assessment. I'm hoping mgmt finally realizes the tech needs to be in big boys hands at this time. My guess as I said earlier is the sunrise biomarker will either tell us bavi is commercially viable soon and the probability of success w/ a biomarker is calculable. If that happens mgmt will have no excuses for selling ATM shares at ten cents on the dollar when it is apparent that less dilutive options are available. (Or SK has been lying for years..)

I believe there are enough shareholders that have had enough of the current mgmt team, particularly the BOD and their self serving behavior to demand change.

Happy New Year